SCHEMBL25690367

SCHEMBL25690367

Cc1cnc(-c2ccc(I)cc2)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.34
CCR5 P51681 1/20 0.34
CCR8 P51685 1/20 0.34
METAP2 P50579 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CNR2 P34972 2/20 0.34
PTGS2 P35354 2/20 0.33
PLG P00747 1/20 0.33
PLAU P00749 1/20 0.33
PLAT P00750 1/20 0.33
ADH5 P11766 1/20 0.33
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
CRHR1 P34998 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17720584 0.87 ALDH1A1 (0.44) CCR1CCR5CCR8METAP2SMN1; SMN2
SCHEMBL28182737 0.81 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1KMT2AMAPTMAPK1
SCHEMBL12970557 0.78 MAP2K4 (0.46)
SCHEMBL12508142 0.74 CNR2 (0.49) SMN1; SMN2ALDH1A1MAPTMAPK1HTT
SCHEMBL13327625 0.71 MAP2K4 (0.49) SMN1; SMN2ALDH1A1KMT2AMAPTMAPK1
SCHEMBL761535 0.70
SCHEMBL3660093 0.70 ATM (0.42) ALDH1A1KMT2AMAPTMAPK1HTT
SCHEMBL27070674 0.68 KMT2A (0.41) CCR1CCR5CCR8SMN1; SMN2ALDH1A1
SCHEMBL17629944 0.68 PLAU (0.40) PLAU
SCHEMBL27432977 0.67 CNR2 (0.53) CCR1CCR5CCR8SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE CCR1 317/4885CCR5 68/4885CCR8 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.